Natascha Verra

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

G C de Gast, Heinz‐Josef Klümpen, Florry A. Vyth‐Dreese et al. · PubMed · 2000 · 60 citations

Progressive Metastatic Melanoma, Immunology, Immunoediting +16

Histological and immunological parameters to predict treatment outcome ofHelicobacter pylori eradication in low-grade gastric MALT lymphoma

Daphne de Jong, Florry A. Vyth‐Dreese, Trees A. M. Dellemijn et al. · The Journal of Pathology · 2001 · 51 citations

Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice

Natascha Verra, Annelies Jorritsma, Kees Weijer et al. · Cancer Research · 2004 · 42 citations · Full text

Infiltration of Activated Dendritic Cells and T Cells in Renal Cell Carcinoma Following Combined Cytokine Immunotherapy

Natascha Verra, Daphne de Jong, Axel Bex et al. · European Urology · 2005 · 34 citations

Urology, Cancer Immunosurveillance, Genitourinary Cancer +9

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

Natascha Verra, Gerard Groenewegen, Henk Mallo et al. · British Journal of Cancer · 2003 · 32 citations · Full text